Gilead's investigational drug presented to American Society of Hypertension annual meeting and expo

FOSTER CITY, Calif. Data from a phase 3 study of an investigational drug from Gilead Sciences for treating resistant hypertension has been accepted as an oral late-breaker presentation at the American Society of Hypertension’s 24th annual Scientific Meeting and Exposition in San Francisco.

Michael Weber, professor of medicine at the State University of New York Downstate Medical College of Medicine in Brooklyn, will present the data on the drug darusentan, an endothelin receptor agonist, on May 8.

Darusentan selectively blocks the endothelin type-A receptor, which causes narrowing of the blood vessels and cell proliferation if endothelin-1 activates it.